Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points.

Slides:

Advertisements

Similar presentations

From: An open day in the metric space

Advertisements

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

Figure 1 The spatial and temporal distribution of diarrhoea rates

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. CONSORT flow diagram.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Error bars represent the mean (s.e.).

pSS: primary SS; Scl: scleroderma.

Figure 1. Selection of papers.

Fig. 1 Flow chart of study selection

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig 1 Perfusion index values at different time intervals in patients with successful and failed blocks. A reference line at PI 3.3 is provided. Horizontal.

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1. Impact ratings for prospective memory lapses for younger (~age 30), middle-age (~age 50), and older (~age 65) adults. From: Daily Memory Lapses.

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

NICE-BAD clinical audit on psoriasis

Figure 1. HR (95% CI) of death from dementia associated with weight or BMI in middle age and in old age. From: Adiposity in middle and old age and risk.

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Fig. 1 Flow chart of the literature search

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

Under osteoporotic conditions, several proinflammatory cytokines ...

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

(A) mSchober in DESIR; (B) mSchober in SPACE; (C) LSF ...

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

(a) Detection of ANETA. NETs were reacted with the ...

AHA: American Heart Association; ALT: ...

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

(A) OA patients with ... (A) OA patients with crystals exhibit an increase in FA levels in SF compared with OA patients without crystals. (B) Patients.

bDMARD: biologic DMARD.

(A) Pelvic X-ray showing diffuse osteoaddensing ...

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

High IFN-α levels were found in patient’s serum, and ...

(A) Strain elastography of left submandibular gland in a patient with ... (A) Strain elastography of left submandibular gland in a patient with SS. An.

Fig. 3 Interrelationship between themes describing the experiences of people with shoulder disorders Unless provided in the caption above, the following.

x-axis, post-partum days. Closed ...

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Rats were treated for 21 days ...

Fig. 1 Flow chart for selection of study subjects

Prevalence and distribution of ...

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

(A–D) Distribution of age (A), mRSS (B), ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Psoriatic target lesion at (A) ...

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

The independent additive value of total greyscale + power Doppler synovitis ... The independent additive value of total greyscale + power Doppler synovitis.

Figure 1. Biofilm susceptibility to antibiotic treatment

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

(A) Serum IgM ... (A) Serum IgM anti-phosphorylcholine (PC) antibodies were diminished in SLE patients (n = 197) compared with controls (n = 99) [60.53.

Fig. 1 Schematic subcategorization of AAV in three clinically relevant disease categories defined by clinical ... Fig. 1 Schematic subcategorization of.

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

LPA groups display vastly different outcomes.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Presentation transcript:

Patients were considered not in MDA (MDA<sup>−</sup>) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA<sup>+</sup>) with a score of 5, 6 or 7 points. MDA: minimal disease activity. From: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement Rheumatology (Oxford). Published online May 24, 2017. doi:10.1093/rheumatology/kex183 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

(A) The percentage of patients failing specific MDA criterion in the MDA subgroups. (B) Percentage of MDA patients failing specific MDA criterion according to gender. (C and D) PRO scores in MDA subgroups. Significance of the comparisons is determined by an independent sample t-test for continues variables and Mann–Whitney U test when non-normally distributed. P < 0.05 was considered significant and indicated with an asterisks. Cutoff points for values were used according to the MDA scoring: VASptGlobal > 20 mm; VASptPain > 15 mm; SJC > 1; TJC > 1; PASI > 1; LEI > 1; HAQ > 0.5. DLQI: Dermatology Quality of Life Index; HADS: Hospital Anxiety and Depression Scale; LEI: Leeds Enthesitis Index; MDA: minimal disease activity; PASI: Psoriasis Area Severity Index; PRO: patient reported outcome; SF-36 MCS: Short Form 36, mental impact of disease; SF-36 PCS: Short Form 36, physical disability; SJC: swollen joint count; TJC: tender joint count; VASptGlobal: the patient global assessment of disease activity on a 0-100 VAS; VASptPain: the patient assessment of pain on a 0-100 VAS; WPAI ADL: Work Productivity Assessment Index, patient perception on impairment in daily life activities. From: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement Rheumatology (Oxford). Published online May 24, 2017. doi:10.1093/rheumatology/kex183 Rheumatology (Oxford) | © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com